Back to search results

Observational Study of MicroRNA in Pancreatic Cancer

This study is looking at how tiny molecules called microRNA (miRNA) in your blood might help us understand pancreatic cancer better. Researchers believe that certain miRNAs could help diagnose pancreatic cancer earlier, predict how the disease might progress, and show how well treatments are working. You could join if you are an adult (18 or older) with stage III or IV pancreatic adenocarcinoma that was initially considered inoperable. The study involves collecting blood samples to analyze your miRNA profile. The goal is to find specific miRNAs that can distinguish pancreatic cancer patients from healthy individuals and track how they change with treatment. The current recruitment status is unclear.

Study design
This is an observational study with a planned enrollment of 200 participants. It is not a treatment study, but rather aims to understand the role of microRNA.
What's involved
If you are in the unresectable pancreatic cancer group, you will have monthly blood draws. If you are in the control group, you will have one blood draw.
Compensation
Not stated in the trial record.
Follow-up
Your miRNA profile will be analyzed through study completion, up to 5 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT04406831

The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer

Recruiting
Not specifiedAges 18+Observational
Nuvance Health
~200 participants
Updated 2026-04-13 on ClinicalTrials.gov
What's tested:Blood draw

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Analysis of miRNA profile
Measured over Through study completion, up to 5 years

Conditions

Pancreatic Cancer Stage III
Pancreatic Cancer Stage IV
Pancreatic Ductal Adenocarcinoma
Pancreatic Neoplasms

Explore related trials

Pancreatic Ductal Adenocarcinoma

NCT04406831

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Nuvance Health

    Norwalk, Connecticutstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Richard Frank, MD · PRINCIPAL_INVESTIGATOR · Nuvance Health

Who to contact

Pramila Krumholtz, RN
[email protected]
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have biopsy proven adenocarcinoma of the pancreas
Have initially inoperable disease, classified as either locally advanced or metastatic disease
Recurrent disease after a Whipple procedure is allowed
Patients who are able to undergo resection after neoadjuvant therapy will continue to be followed after resection
Have radiographically measurable disease
Have an ECOG performance status of 2 or less
Be willing to contribute the required information and specimens
Provide written signed consent to participate

Exclusion

Having received prior anti-cancer treatments for metastatic pancreatic cancer
Concurrently receiving systemic therapy for another cancer except androgen deprivation therapy for stable/controlled prostate cancer
Presence of other active cancer except for: adequately treated local basal or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for \>1 year prior to start of trial. Other adequately treated Stage 1 or 2 cancer currently in complete remission, or any other cancer that has been in complete remission for \> 5 years is allowable

What this trial measures

  • Analysis of miRNA profileThrough study completion, up to 5 years

    Analyze the miRNA profiles present at each time point.